NCT07412704PHASE1, PHASE2Recruiting

A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis

Bristol-Myers Squibb

Start Date

9/15/2026

Completion Date

9/2/2030

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the preliminary evidence of disease-modifying effect of BMS-986528 in participants with refractory, difficult-to-treat rheumatoid arthritis (RA).

Eligibility Criteria

Age Range: 18 years to 65 years

Inclusion Criteria \- Adult participants with rheumatoid arthritis (RA) who meet definition of difficult-to-treat. Exclusion Criteria * Juvenile arthritis or onset of inflammatory arthritis before age 18. * Seronegative RA participants in whom polymyalgia rheumatica has not been ruled out. * Active fibromyalgia with pain symptoms or signs that would interfere with joint assessment. * Other protocol-defined Inclusion/Exclusion criteria apply.

Interventions

DRUG

BMS-986528

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Arthritis, Rheumatoid

Locations

Local Institution - 0068

La Jolla, California 92037

United States

Local Institution - 0070

Loma Linda, California 92354

United States

Local Institution - 0069

Palo Alto, California 94304-2210

United States

Local Institution - 0050

Aurora, Colorado 80045

United States

Colorado Blood Cancer Institute

Denver, Colorado 80218

United States

Local Institution - 0055

South Miami, Florida 33143

United States

Local Institution - 0081

New York, New York 10016

United States

Local Institution - 0079

New York, New York 10029

United States

Local Institution - 0066

Portland, Oregon 97239

United States

Local Institution - 0071

Philadelphia, Pennsylvania 19107

United States

Local Institution - 0051

DeSoto, Texas 75115

United States

Local Institution - 0048

Merksem, Flanders 2170

Belgium

Local Institution - 0049

Leuven, 3000

Belgium

Local Institution - 0083

Aparecida de Goiânia, Goiás 74935-530

Brazil

Local Institution - 0033

Porto Alegre, Rio Grande do Sul 90050-010

Brazil

Local Institution - 0082

Valinhos, São Paulo 13271-130

Brazil

Local Institution - 0006

Beijing, Beijing Municipality 100091

China

Local Institution - 0080

Guangzhou, Guangdong 510260

China

Local Institution - 0010

Zhengzhou, Henan 450000

China

Local Institution - 0007

Nanchang, Jiangxi 330006

China

Local Institution - 0020

Shanghai, Shanghai Municipality 200040

China

Local Institution - 0001

Shanghai, Shanghai Municipality 200127

China

Local Institution - 0040

München, Bavaria 81377

Germany

Charité Research Organisation

Berlin, 10117

Germany

Local Institution - 0021

Cologne, 50937

Germany

Local Institution - 0028

Herne, 44652

Germany

St. Josef-Stift Sendenhorst

Sendenhorst, 48324

Germany

Local Institution - 0019

Rozzano, Milano 20089

Italy

Local Institution - 0017

Roma, 00168

Italy

Local Institution - 0053

México, 14080

Mexico

Local Institution - 0023

Józefów, Masovian Voivodeship 05-410

Poland

CHUAC-Complejo Hospitalario Universitario A Coruña

A Coruña, A Coruña [La Coruña] 15006

Spain

Hospital Universitario Reina Sofia

Córdoba, 14004

Spain

Universitaetsspital Bern - Inselspital

Bern, 3010

Switzerland

Local Institution - 0027

Geneva, 1211

Switzerland

Local Institution - 0060

Ivano-Frankivsk, Ivano-Frankivsk Oblast 76008

Ukraine

Local Institution - 0063

Poltava, Poltava Oblast 36011

Ukraine

Local Institution - 0064

Kyiv, 01135

Ukraine

Local Institution - 0061

Ternopil, 46002

Ukraine